April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Grants FTD to Ofra-Vec Plus Paclitaxel for Platinum-Resistant Ovarian Cancer
April 26th 2022The FDA has granted fast track designation to ofranergene obadenovec in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer. The agent is under investigation in the phase 3 OVAL study.
Read More
Tewari Reviews Maintenance Treatments for Patients With Advanced Ovarian Cancer
April 18th 2022During a Targeted Oncology case-based roundtable discussion, Krishnansu S. Tewari, MD, discussed the use of bevacizumab, niraparib, and olaparib for patients who have completed primary chemotherapy for advanced ovarian cancer.
Read More
Early Signs of Clinical Promise Noted for Neoadjuvant Chemoimmunotherapy in Advanced Ovarian Cancer
April 13th 2022Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.
Read More
INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer Recommended to Continue
March 30th 2022Tumor treating fields in combination with paclitaxel in patients with platinum-resistant ovarian cancer, has been recommended by an independent data monitoring committee to proceed to the final analysis based on data from the phase 3 INNOVATE-3 trial.
Read More
Ovarian Cancer Patient Case: Prognosis and Molecular Testing
March 17th 2022Expert Leslie Randall, MD, discusses the case of a 71-year-old woman who is diagnosed with ovarian cancer. Dr. Randall reviews data with PARP inhibitors and rationale for use of maintenance therapy in patients with platinum-sensitive disease.
Watch
Trametinib Excels Over Standard of Care in Patients with Rare Ovarian Cancer
February 8th 2022Findings around trametinib as treatment of patients with an ovarian cancer subtype represent a major advance in the treatment of women with this rare ovarian and peritoneal cancer subtype, according to David Gershenson, MD.
Read More
Case 2: Monitoring Adverse Reactions With Niraparib Maintenance in Ovarian Cancer
February 4th 2022Cecelia H. Boardman, MD, John K. Chan, MD, and Thomas C. Krivak, MD, share strategies for monitoring adverse events and the optimal duration for niraparib maintenance therapy for a patient with advanced ovarian cancer.
Watch
Case 2: Maintenance Strategies for Advanced Ovarian Cancer
February 4th 2022Thomas C. Krivak, MD; John K. Chan, MD; Cecelia H. Boardman, MD; and Ashley Farione, PA-C, review the optimal approach to maintenance therapeutic options for a patient with stage III, high-grade serous epithelial ovarian cancer.
Watch
Case 2: Stage III, High-Grade Serous Epithelial Ovarian Cancer
February 4th 2022Experts in gynecologic oncology review the case of a 71-year-old woman who is diagnosed with stage III, high-grade serous epithelial ovarian cancer, and comment on their approach to genetic testing in the frontline setting.
Watch